Actin Cytoskeleton Deregulation Confers Midostaurin Resistance in FLT3-Mutant Acute Myeloid Leukemia

Midostaurin resistance was overcome by a combination of midostaruin, the BCL-2 inhibitor venetoclax and the RAC1 inhibitor Eht1864 in midostaurin-resistant acute myeloid leukemia (AML) cell lines and primary samples, providing the first evidence of a potential new treatment approach to eradicate FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication + AML.